{"id":972337,"date":"2026-06-15T17:58:07","date_gmt":"2026-06-15T21:58:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\/"},"modified":"2026-06-15T17:58:07","modified_gmt":"2026-06-15T21:58:07","slug":"murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\/","title":{"rendered":"Murchinson Criticizes the Nano Dimension Board of Directors\u2019 Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics"},"content":{"rendered":"

<\/p>\n

Murchinson Criticizes the Nano Dimension Board of Directors\u2019 Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics<\/b><\/p>\n

Believes the Proposed Transaction Represents a Misallocation of Corporate Resources That Would Significantly Dilute Existing Shareholders<\/i><\/p>\n

Finds It Deeply Concerning That This Morning’s Conference Call Offered Shareholders Little Beyond Buzzwords and Provided No Opportunity to Ask Questions Regarding a Transaction That Materially Impacts the Future of the Company<\/i><\/p>\n

TORONTO–(BUSINESS WIRE<\/a>)–
\nMurchinson Ltd. (collectively with its affiliates and funds it advises and\/or sub-advises, “Murchinson” or “we”), a significant shareholder with approximately 7.4% of the outstanding shares of Nano Dimension Ltd. (NASDAQ: NNDM) (“Nano” or the “Company”), today commented on Nano\u2019s announcement that it has signed a non-binding term sheet with Infinite Epigenetics (\u201cInfinite\u201d or \u201cInfinite Epigenetics\u201d) to form a publicly traded, AI-powered health and diagnostics company.1<\/sup><\/p>\n

\nAmong the most notable omissions from this morning\u2019s conference call was any opportunity for Nano shareholders to ask questions regarding the proposed Infinite transaction. This Board of Directors (the \u201cBoard\u201d), much like the previous Board under Yoav Stern, appears unwilling to answer necessary questions from shareholders about its decision-making. We therefore outlined below the questions we had intended to raise to CEO Dave Stehlin, in the interest of the transparency shareholders deserve.<\/p>\n

    \n
  1. \nHow is this transaction meaningfully different from a SPAC? On the most recent earnings call, Mr. Stehlin stated that Nano is \u201cabsolutely not a SPAC.<\/i>\u201d Yet the proposed transaction with Infinite appears to contradict that statement, effectively transforming Nano into a SPAC. One difference that we do note is that, in a traditional SPAC, shareholders at least have the option to redeem their shares for cash, while Nano\u2019s shareholders don\u2019t appear to even have that right in the proposed deal.<\/p>\n<\/li>\n
  2. \nWhat relevant qualifications do the Board members have to evaluate a business operating in epigenetics? Do any of the Board members have relevant education or industry experience to properly determine if this target is the right one?<\/p>\n<\/li>\n
  3. \nWhat direct or indirect consideration \u2013 whether in the form of cash, stock, warrants, options, employment arrangements or Board seats \u2013 is any current Board member expected to receive upon completion of this transaction?<\/p>\n<\/li>\n
  4. \nWhy did the Board agree to a termination fee that appears particularly prohibitive to Nano, including in circumstances where Nano shareholders could effectively cost the Company as much as $10 million simply by rejecting a deeply flawed transaction?2<\/sup> Why did the Board also agree to \u201cspecific performance<\/i>\u201d and \u201cbest efforts<\/i>\u201d provisions? Given the Desktop Metal debacle, why is the Board once again following a deal framework so closely associated with Yoav Stern\u2019s failed strategy?<\/p>\n<\/li>\n
  5. \nDoes the Board recognize that the Company\u2019s 15% stock price decline following this morning\u2019s announcement sends a clear message: shareholders see this proposed transaction as value-destructive?<\/p>\n<\/li>\n<\/ol>\n

    \nRegarding the supposed \u201cstrategic flexibility<\/i>\u201d repeatedly referenced by Mr. Stehlin,3<\/sup> Murchinson believes the proposed transaction is not only a poor business decision, but also inconsistent with the understanding on which Nano raised capital from shareholders. When Nano raised capital through stock issuances, investors were presented with a business model centered on a \u201crazor and blades<\/i>\u201d strategy tied to the Company\u2019s 3D printers.4<\/sup> Even in Nano\u2019s most recent annual report, there is no disclosure suggesting the Company has \u201cstrategic flexibility<\/i>\u201d to pursue any deal the Board thinks is fair game.<\/p>\n

    \nMurchinson also notes that retired General Michael X. Garrett is listed as an advisor to Infinite Epigenetics.5<\/sup> Shareholders should recall that Gen. Garrett served on Nano\u2019s Board when it unanimously approved the Desktop Metal acquisition.6<\/sup><\/p>\n

    \nWe question whether the Board expects shareholders to ignore this connection. Gen. Garrett was a member of the Nano Board when it destroyed hundreds of millions of dollars of the Company\u2019s capital in the Desktop Metal deal and now is involved in another proposed transaction that we expect to destroy Nano\u2019s remaining cash if consummated.<\/p>\n

    \nMurchinson intends to continue objecting to speculative initiatives that appear entrenchment-driven and value-destructive, such as the proposed Infinite Epigenetics transaction. We call on the Board to provide full and direct answers to shareholders regarding a proposed transaction that could materially impact the future of their company.<\/p>\n

    About Murchinson
    \n
    <\/b>Founded in 2012 and based in Toronto, Canada, Murchinson is an alternative asset management firm that serves institutional investors, family offices and qualified clients. The firm has extensive experience capturing the best returning opportunities across global markets. Murchinson\u2019s multi-strategy approach allows it to execute investments at all points in the market cycle with fluid allocation between strategies. Our team targets corporate action, distressed investing, private equity and structured finance situations, leveraging its broad market experience with a variety of specialized products and sophisticated hedging techniques to deliver alpha within a risk-averse mandate. Learn more at     www.murchinsonltd.com<\/a>.<\/p>\n

    Cautionary Statement Regarding Forward-Looking Statements
    \n
    <\/b>This press release contains forward-looking information within the meaning of applicable securities laws. In general, forward-looking information refers to disclosure about future conditions, courses of action, and events. All statements contained in this press release that are not clearly historical in nature or that necessarily depend on future events are forward-looking, and the use of any of the words \u201canticipates\u201d, \u201cbelieves\u201d, \u201cexpects\u201d, \u201cintends\u201d, \u201cplans\u201d, \u201cwill\u201d, \u201cwould\u201d, and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations of Murchinson and currently available information. Forward-looking statements are not guarantees of future performance, involve certain risks and uncertainties that are difficult to predict, and are based upon assumptions as to future events that may not prove to be accurate. Murchinson undertakes no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities legislation.<\/p>\n

    Disclaimer
    \n
    <\/b>The information contained or referenced herein is for information purposes only in order to provide the views of Murchinson and the matters which Murchinson believes to be of concern to shareholders described herein. The information is not tailored to specific investment objections, the financial situations, suitability, or particular need of any specific person(s) who may receive the information, and should not be taken as advice in considering the merits of any investment decision. The views expressed herein represent the views and opinions of Murchinson, whose opinions may change at any time and which are based on analyses of Murchinson and its advisors. In addition, the information contained herein is being publicly disclosed without prejudice and shall not be construed to prejudice any of Murchinson\u2019s rights, demands, grounds and\/or remedies under any contract and\/or law, including any pending lawsuits.<\/p>\n

    1<\/sup> Press Release: Nano Dimension Signs Term Sheet with Infinite Epigenetics to Form a Publicly Traded, AI-Powered Preventive Health and Diagnostics Company<\/a> (June 15, 2026).
    \n
    2<\/sup>    https:\/\/www.sec.gov\/Archives\/edgar\/data\/1643303\/000110465926073778\/tm2617934d1_ex99-1.htm
    \n<\/a>
    3<\/sup> Press Release:     Nano Dimension Issues Letter from Chief Executive Officer, David Stehlin<\/a> (June 5, 2026); M&A Call on June 15, 2026.
    \n
    4<\/sup> For example:     https:\/\/www.sec.gov\/Archives\/edgar\/data\/1643303\/000121390021009721\/ea135799-424b5_nanodimen.htm
    \n<\/a>
    5<\/sup>    https:\/\/www.sec.gov\/Archives\/edgar\/data\/1643303\/000110465926073777\/tm2617934d1_ex99-3.htm
    \n<\/a>
    6<\/sup> Press Release:     Nano Dimension to Acquire Desktop Metal, Creating a Leader in Additive Manufacturing<\/a> (July 3, 2024).<\/p>\n

    \"\"<\/p>\n

    View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260615954399\/en\/<\/a><\/span><\/p>\n

    \nLongacre Square Partners
    \n
    murchinson@longacresquare.com<\/a><\/p>\n

    KEYWORDS:<\/b> North America Canada<\/p>\n

    INDUSTRY KEYWORDS:<\/b> Asset Management Professional Services Finance<\/p>\n

    MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

    Murchinson Criticizes the Nano Dimension Board of Directors\u2019 Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics Believes the Proposed Transaction Represents a Misallocation of Corporate Resources That Would Significantly Dilute Existing Shareholders Finds It Deeply Concerning That This Morning’s Conference Call Offered Shareholders Little Beyond Buzzwords and Provided No Opportunity to Ask Questions Regarding a Transaction That Materially Impacts the Future of the Company TORONTO–(BUSINESS WIRE)– Murchinson Ltd. (collectively with its affiliates and funds it advises and\/or sub-advises, “Murchinson” or “we”), a significant shareholder with approximately 7.4% of the outstanding shares of Nano Dimension Ltd. (NASDAQ: NNDM) (“Nano” or the “Company”), today commented on Nano\u2019s announcement that it has signed a non-binding term sheet with Infinite Epigenetics … <\/p>\n

    Continue reading “Murchinson Criticizes the Nano Dimension Board of Directors\u2019 Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-972337","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMurchinson Criticizes the Nano Dimension Board of Directors\u2019 Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Murchinson Criticizes the Nano Dimension Board of Directors\u2019 Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Murchinson Criticizes the Nano Dimension Board of Directors\u2019 Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics Believes the Proposed Transaction Represents a Misallocation of Corporate Resources That Would Significantly Dilute Existing Shareholders Finds It Deeply Concerning That This Morning’s Conference Call Offered Shareholders Little Beyond Buzzwords and Provided No Opportunity to Ask Questions Regarding a Transaction That Materially Impacts the Future of the Company TORONTO–(BUSINESS WIRE)– Murchinson Ltd. (collectively with its affiliates and funds it advises and\/or sub-advises, “Murchinson” or “we”), a significant shareholder with approximately 7.4% of the outstanding shares of Nano Dimension Ltd. (NASDAQ: NNDM) (“Nano” or the “Company”), today commented on Nano\u2019s announcement that it has signed a non-binding term sheet with Infinite Epigenetics … Continue reading "Murchinson Criticizes the Nano Dimension Board of Directors\u2019 Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T21:58:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260615954399r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Murchinson Criticizes the Nano Dimension Board of Directors\u2019 Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics\",\"datePublished\":\"2026-06-15T21:58:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\\\/\"},\"wordCount\":1236,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260615954399r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\\\/\",\"name\":\"Murchinson Criticizes the Nano Dimension Board of Directors\u2019 Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260615954399r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-06-15T21:58:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260615954399r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260615954399r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Murchinson Criticizes the Nano Dimension Board of Directors\u2019 Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Murchinson Criticizes the Nano Dimension Board of Directors\u2019 Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\/","og_locale":"en_US","og_type":"article","og_title":"Murchinson Criticizes the Nano Dimension Board of Directors\u2019 Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics - Market Newsdesk","og_description":"Murchinson Criticizes the Nano Dimension Board of Directors\u2019 Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics Believes the Proposed Transaction Represents a Misallocation of Corporate Resources That Would Significantly Dilute Existing Shareholders Finds It Deeply Concerning That This Morning’s Conference Call Offered Shareholders Little Beyond Buzzwords and Provided No Opportunity to Ask Questions Regarding a Transaction That Materially Impacts the Future of the Company TORONTO–(BUSINESS WIRE)– Murchinson Ltd. (collectively with its affiliates and funds it advises and\/or sub-advises, “Murchinson” or “we”), a significant shareholder with approximately 7.4% of the outstanding shares of Nano Dimension Ltd. (NASDAQ: NNDM) (“Nano” or the “Company”), today commented on Nano\u2019s announcement that it has signed a non-binding term sheet with Infinite Epigenetics … Continue reading \"Murchinson Criticizes the Nano Dimension Board of Directors\u2019 Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-15T21:58:07+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260615954399r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Murchinson Criticizes the Nano Dimension Board of Directors\u2019 Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics","datePublished":"2026-06-15T21:58:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\/"},"wordCount":1236,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260615954399r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\/","name":"Murchinson Criticizes the Nano Dimension Board of Directors\u2019 Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260615954399r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-06-15T21:58:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260615954399r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260615954399r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/murchinson-criticizes-the-nano-dimension-board-of-directors-decision-to-pursue-a-seemingly-deeply-flawed-transaction-with-infinite-epigenetics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Murchinson Criticizes the Nano Dimension Board of Directors\u2019 Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/972337","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=972337"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/972337\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=972337"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=972337"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=972337"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}